103
Views
1
CrossRef citations to date
0
Altmetric
Review

Hiv Microbicides: State-Of-The-Art and New Perspectives on the Development of Entry Inhibitors

, , &
Pages 1141-1159 | Published online: 12 Jul 2010
 

Abstract

Since the discovery of HIV at the beginning of the 1980s, numerous efforts have been devoted to the search of an efficient vaccine. There are at least 25 drugs available for HIV treatment, but no cure is available. The observation that therapy for HIV disease is life long and that these drugs are associated with a number of side effects underlines the need for approaches aimed at preventing rather than treating infection. Additionally, the economic burden of treatment for the HIV infection occupies an increasing share of healthcare expenditure, making current practices likely to become difficult to sustain in the long run. Unfortunately, no effective vaccine for this disease is foreseeable in the near future. Microbicides could be an alternate way to build preventative approaches to HIV infection. Strategies based on preventing the virus from reaching its target cells seem to have some room for development and application. In this review we explore the state-of-the-art of available microbicides, focusing on HIV entry inhibitors. In addition, we discuss new compounds that show anti-HIV activity, which could be effective candidates.

Financial & competing interests disclosure

The authors thank the following grants for support: Azioni Integrate Italia-Spagna (IT074ABCCM and HI2005–0212); the Ministry of Science and Innovation (MICINN, CTQ2008-01694); the FIRB program CHEM-PROFARMANET (RBPR05NWWC); Marie Curie ITN FP7 project CARMUSYS (PITN-GA-2008–213592); Istituto Superiore di Sanita’ ‘Programma Nazionale di Ricerca sull’ AIDS‘; the EMPRO and AVIP EC WP6 Projects; the nGIN EC WP7 Project; the Japan Health Science Foundation; 2008 Ricerca Finalizzata [Italian Ministry of Health] and 2008 Ricerca Corrente [Italian Ministry of Health]. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript, apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

The authors thank the following grants for support: Azioni Integrate Italia-Spagna (IT074ABCCM and HI2005–0212); the Ministry of Science and Innovation (MICINN, CTQ2008-01694); the FIRB program CHEM-PROFARMANET (RBPR05NWWC); Marie Curie ITN FP7 project CARMUSYS (PITN-GA-2008–213592); Istituto Superiore di Sanita’ ‘Programma Nazionale di Ricerca sull’ AIDS‘; the EMPRO and AVIP EC WP6 Projects; the nGIN EC WP7 Project; the Japan Health Science Foundation; 2008 Ricerca Finalizzata [Italian Ministry of Health] and 2008 Ricerca Corrente [Italian Ministry of Health]. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript, apart from those disclosed.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.